Kite, a Gilead Company

Clinical trials sponsored by Kite, a Gilead Company, explained in plain language.

Now part of Gilead Sciences, Inc. GILD NASDAQ

A cell therapy company focused on CAR-T treatments for cancer, owned by Gilead Sciences.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

One-Time infusion aims to build cancer killers inside the body Results expected Oct 2026 (estimated)
New immune cell therapy takes on tough lymphoma Results expected Nov 2026 (estimated)
Engineered immune cells take on Hard-to-Treat myeloma Results expected Dec 2026 (estimated)
CAR T-Cell therapy takes on tough blood cancers in japanese trial Results expected Jul 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 5 Not yet finished but already full! 10 Completed 6 Terminated 1

Experimental CAR T-Cell therapy targets rare B-Cell cancers

Disease control Stopped early

This phase 2 study tested a treatment called brexucabtagene autoleucel, a CAR T-cell therapy made from a patient's own immune cells, for four rare B-cell cancers: Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia. The trial enrolled …

Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control

Last updated Jun 27, 2026 11:00 UTC

Kite, a Gilead Company

Upcoming readouts

Experimental CAR T-Cell therapy targets rare B-Cell cancers